Novel Microdevices, Baltimore, MD, USA
noveldx.com/

NOVEL DX
RAPID MOLECULAR DIAGNOSTIC
Diagnostic for sexually transmitted infections

The Novel Diagnostic device will offer a rapid point-of-care molecular test for the identification of sexually transmitted infections (STIs) and will detect antibiotic resistant pathogens, including Chlamydia trachomatis and Neisseria gonorrhoeae. Test results will inform antimicrobial treatment decisions in about 25 minutes. Novel’s new device would diagnose infections from a vaginal swab or urine sample, and detect antibiotic-resistant bacteria, including those resistant to ciprofloxacin and 3rd generation cephalosporins, the only antibiotics that are still effective as treatments for most strains of the gonorrhoeae bacteria. The Novel Dx uses an onboard innovative sample-preparation technology. The instrument is low power, very portable and easy to use. Suited for use in clinics, primary healthcare settings and laboratories around the world including in low-resource settings and low-and middle-income countries. Gonorrhea is a disease affecting an estimated 78 million people world-wide, particularly women in low- and middle-income countries.

Current Development Stage: Feasibility

CARB-X Investment: Initial investment of up to $3.6m with potential option payments up to $10.2m.

Initial CARB-X Investment Date: November 1, 2020